The Clinical Course of Multiple Myeloma in the Era of Novel Agents: A Retrospective, Single-Center, Real-World Study
- Standort
-
Deutsche Nationalbibliothek Frankfurt am Main
- Umfang
-
1 Online-Ressource.
- Sprache
-
Englisch
- Erschienen in
-
The Clinical Course of Multiple Myeloma in the Era of Novel Agents: A Retrospective, Single-Center, Real-World Study ; volume:1 ; number:4 ; day:12 ; month:8 ; year:2019 ; pages:220-228 ; date:12.2019
Clinical hematology international ; 1, Heft 4 (12.8.2019), 220-228, 12.2019
- Urheber
-
Szabo, Agoston Gyula
Iversen, Katrine Fladeland
Möller, Sören
Plesner, Torben
- Beteiligte Personen und Organisationen
-
SpringerLink (Online service)
- DOI
-
10.2991/chi.d.190805.002
- URN
-
urn:nbn:de:101:1-2404230750565.546057945444
- Rechteinformation
-
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Letzte Aktualisierung
- 14.08.2025, 10:53 MESZ
Datenpartner
Dieses Objekt wird bereitgestellt von:
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Beteiligte
- Szabo, Agoston Gyula
- Iversen, Katrine Fladeland
- Möller, Sören
- Plesner, Torben
- SpringerLink (Online service)
Ähnliche Objekte (12)
Poor outcomes of immunoglobulin D multiple myeloma patients in the era of novel agents: a single-center experience
Emerging agents and regimens for multiple myeloma
Multiple Myeloma Management in COVID-19 Era
Real-world data on prognosis and outcome of primary plasma cell leukemia in the era of novel agents: a multicenter national study by the Greek Myeloma Study Group
Real-World Clinical Efficacy of Antifibrotic Agents for Idiopathic Pulmonary Fibrosis: A Single-Center Retrospective Study in Japan
New agents in the Treatment of Myeloma Bone Disease
R2-ISS staging combined with circulating plasma cells improves risk stratification for newly diagnosed multiple myeloma: a single-center real-world study
Front-line therapies for elderly patients with transplant-ineligible multiple myeloma and high-risk cytogenetics in the era of novel agents
Teclistamab in relapsed refractory multiple myeloma: multi-institutional real-world study
Cervical debranching in the endovascular era : a single-center experience
Prognosis of Liposarcoma Patients in Modern ERA: Single-Center Experience
The impact of high-risk cytogenetic abnormalities in extramedullary multiple myeloma in the era of novel agents: insights from a multicenter study
Poor outcomes of immunoglobulin D multiple myeloma patients in the era of novel agents: a single-center experience
Emerging agents and regimens for multiple myeloma
Multiple Myeloma Management in COVID-19 Era
Real-world data on prognosis and outcome of primary plasma cell leukemia in the era of novel agents: a multicenter national study by the Greek Myeloma Study Group
Real-World Clinical Efficacy of Antifibrotic Agents for Idiopathic Pulmonary Fibrosis: A Single-Center Retrospective Study in Japan
New agents in the Treatment of Myeloma Bone Disease
R2-ISS staging combined with circulating plasma cells improves risk stratification for newly diagnosed multiple myeloma: a single-center real-world study
Front-line therapies for elderly patients with transplant-ineligible multiple myeloma and high-risk cytogenetics in the era of novel agents
Teclistamab in relapsed refractory multiple myeloma: multi-institutional real-world study
Cervical debranching in the endovascular era : a single-center experience
Prognosis of Liposarcoma Patients in Modern ERA: Single-Center Experience
The impact of high-risk cytogenetic abnormalities in extramedullary multiple myeloma in the era of novel agents: insights from a multicenter study
Poor outcomes of immunoglobulin D multiple myeloma patients in the era of novel agents: a single-center experience
Emerging agents and regimens for multiple myeloma
Multiple Myeloma Management in COVID-19 Era
Real-world data on prognosis and outcome of primary plasma cell leukemia in the era of novel agents: a multicenter national study by the Greek Myeloma Study Group
Real-World Clinical Efficacy of Antifibrotic Agents for Idiopathic Pulmonary Fibrosis: A Single-Center Retrospective Study in Japan
New agents in the Treatment of Myeloma Bone Disease
R2-ISS staging combined with circulating plasma cells improves risk stratification for newly diagnosed multiple myeloma: a single-center real-world study
Front-line therapies for elderly patients with transplant-ineligible multiple myeloma and high-risk cytogenetics in the era of novel agents
Teclistamab in relapsed refractory multiple myeloma: multi-institutional real-world study
Cervical debranching in the endovascular era : a single-center experience
Prognosis of Liposarcoma Patients in Modern ERA: Single-Center Experience